COLL Q3 2025 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$209M+31.4% YoY

Gross Profit

$129M61.7% margin

Operating Income

$64M30.4% margin

Net Income

$32M15.0% margin

EPS (Diluted)

$0.84

QoQ Revenue Growth

+11.4%

Cash Flow

Operating Cash Flow

$78M

Free Cash Flow

$78M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$1.3B

Stockholders' Equity

$275M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$209M	$159M	+31.4%
Gross Profit	$129M	$97M	+33.4%
Operating Income	$64M	$35M	+82.6%
Net Income	$32M	$9M	+237.5%

Revenue Segments

Belbuca

$58M35%

Xtampza ER

$50M30%

Nucynta IR

$32M19%

Nucynta ER

$23M14%

Symproic

$4M2%